Does Amerigroup Cover Vyvanse?

What Amerigroup Is and How Its Formulary Works

Amerigroup is a Medicaid managed care organization (MCO) that operates as a subsidiary of Elevance Health (formerly Anthem). It administers Medicaid benefits in more than 20 states, covering approximately 5 million members as of 2025. Each state contract produces a separate formulary, which is the list of medications Amerigroup will pay for under that state's Medicaid program.

This matters for Vyvanse because a drug can be covered in one state and restricted or excluded in another. Amerigroup's Texas formulary, for example, operates under the Texas Vendor Drug Program's preferred drug list, while the Georgia plan follows a different set of clinical criteria established in partnership with the Georgia Department of Community Health 1. Medicaid law under the Omnibus Budget Reconciliation Act of 1990 requires state Medicaid programs to cover all FDA-approved medications from manufacturers that have signed a federal rebate agreement. Takeda (now Lundbeck for the Vyvanse portfolio) participates in the federal rebate program, which means Amerigroup cannot categorically exclude Vyvanse 2. The plan can, however, require prior authorization, impose step therapy, or place the drug on a non-preferred tier.

To find your specific state formulary, log in to the Amerigroup member portal or call the number on the back of your member ID card. Request the "preferred drug list" or "formulary" for your state.

Vyvanse: FDA Approval, Mechanism, and Clinical Evidence

Lisdexamfetamine dimesylate received FDA approval in February 2007 for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 12 3. The indication later expanded to include adolescents, adults with ADHD, and adults with moderate-to-severe binge eating disorder (BED). The drug is a prodrug of dextroamphetamine. It requires enzymatic cleavage in red blood cells to release the active molecule, which results in a smoother pharmacokinetic profile compared to immediate-release amphetamine formulations.

In the key phase III trial by Biederman et al. (2007, N=290), children receiving lisdexamfetamine 30 mg, 50 mg, or 70 mg daily showed significant improvement on the ADHD Rating Scale IV compared to placebo, with effect sizes ranging from 1.28 to 1.60 across dose groups (P<0.001 for all doses vs. placebo) 4. A separate 12-month open-label extension confirmed durability of response without significant tachyphylaxis. For binge eating disorder, the phase III trial (N=724) demonstrated a reduction from a mean of 4.5 binge days per week at baseline to 0.8 days per week at 12 weeks for the 50-70 mg dose group, compared to 2.3 days per week for placebo 5.

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends FDA-approved medications for ADHD (including lisdexamfetamine) as first-line pharmacotherapy for children aged 6 and older, alongside behavioral therapy 6. This guideline is relevant because Medicaid MCOs, including Amerigroup, generally align prior authorization criteria with published guidelines from organizations like the AAP.

Prior Authorization Requirements for Vyvanse on Amerigroup

Prior authorization (PA) is the main barrier between an Amerigroup member and a filled Vyvanse prescription. The PA process requires your prescriber to submit clinical documentation proving that the medication is medically necessary. Expect it.

Common PA criteria across Amerigroup state plans include:

Confirmed diagnosis. The member must have a documented diagnosis of ADHD (ICD-10 codes F90.0, F90.1, F90.2, F90.8, F90.9) or binge eating disorder (F50.81). A diagnosis alone is often insufficient. Amerigroup typically requires documentation of symptom severity, functional impairment in at least two settings (school and home for children, work and home for adults), and the method of assessment used.

Step therapy. Many Amerigroup state plans require a trial and failure of at least one preferred stimulant before approving Vyvanse. The most commonly required first-step agents are generic methylphenidate extended-release and generic mixed amphetamine salts (the generic form of Adderall). "Failure" can mean inadequate symptom control at an adequate dose and duration (typically 4-6 weeks), intolerable side effects, or a documented contraindication 7.

Age restrictions. Some state plans restrict stimulant coverage for children under age 6, consistent with the FDA-approved age range for lisdexamfetamine. For preschool-aged children (ages 4-5), the AAP recommends behavioral therapy as first-line treatment, with methylphenidate considered if behavioral therapy alone is insufficient 6.

Quantity limits. Vyvanse is typically limited to 30 capsules per 30-day fill, consistent with once-daily dosing. Prescriptions written for quantities exceeding this limit will trigger an automatic rejection at the pharmacy.

Your prescriber's office handles most of the PA paperwork. The typical turnaround time is 24 to 72 hours for standard requests. Urgent or expedited reviews (for situations where a delay could seriously harm the patient) must be completed within 24 hours under federal Medicaid regulations 8.

Generic Lisdexamfetamine: A Game-Changing Development for Coverage

The FDA approved the first generic lisdexamfetamine capsules in August 2023, and multiple manufacturers (including Alvogen, Teva, and others) now produce the generic version 9. This is the single most important development for Amerigroup coverage of this medication.

Generic availability shifts the economics dramatically. Before generics, brand-name Vyvanse carried a wholesale acquisition cost (WAC) exceeding $400 per month. Generic versions reduced that figure by approximately 40-60%, depending on the manufacturer and pharmacy. For Medicaid plans like Amerigroup, this means:

The generic is far more likely to land on a preferred tier. Several Amerigroup state plans have already moved generic lisdexamfetamine to a preferred position, reducing or eliminating step therapy requirements that previously applied to brand Vyvanse. Federal Medicaid rebates on generic products further reduce the net cost to the plan, making approval decisions easier.

If your prescriber writes for "lisdexamfetamine" (the generic name) rather than "Vyvanse" (the brand name), the pharmacy will automatically dispense the generic unless a "dispense as written" (DAW) code is applied. For most patients, the generic is therapeutically equivalent. The FDA's bioequivalence standards require that generic formulations deliver the active drug within 80-125% of the reference product's rate and extent of absorption 10.

If your Amerigroup plan denies brand-name Vyvanse, ask your prescriber whether the generic would be appropriate. In many cases, this alone resolves the coverage issue.

What Vyvanse Costs on Amerigroup Plans

Medicaid copays are regulated by federal and state law. Under the Deficit Reduction Act and subsequent CMS guidance, most Medicaid beneficiaries pay nominal copays, and certain populations (children under 18, pregnant women, and individuals in institutions) are often exempt from copays entirely 11.

For adult Amerigroup members who do owe a copay, the typical structure looks like this: preferred generic medications carry a $1 to $3.70 copay per prescription. Non-preferred generics and preferred brand-name drugs may carry copays up to $3.70 in most states. Non-preferred brand-name drugs can carry higher copays, though Medicaid caps these amounts based on household income. No Medicaid beneficiary can be denied a medically necessary prescription for inability to pay the copay. This is a federal protection.

If you receive a cost estimate from the pharmacy that seems too high, verify the following: confirm that the pharmacy is billing your Amerigroup plan (not running it as a cash-pay or commercial insurance claim), confirm that the prescription is written for the generic, and confirm that any required prior authorization has been approved. Billing errors at the pharmacy level are a common cause of unexpected high costs on Medicaid prescriptions.

What to Do If Amerigroup Denies Vyvanse Coverage

A denial is not the final answer. Medicaid managed care plans are required by federal law to provide a formal appeals process, and the success rates on appeal are higher than most patients realize.

Step 1: Read the denial letter. Amerigroup must send a written notice explaining why the medication was denied and what criteria were not met. This letter is your roadmap for the appeal. Common denial reasons include missing documentation, failure to complete step therapy, diagnosis not matching the approved indication, or the prescriber not responding to the plan's request for additional information.

Step 2: File a plan-level appeal. Your prescriber can submit additional documentation addressing the specific reason for denial. For step therapy denials, this means documenting prior medication trials. For clinical necessity, this may include standardized ADHD rating scale scores (such as the Conners or Vanderbilt scales), records of functional impairment, and a letter explaining why alternative medications are not appropriate for this specific patient. According to the American Academy of Child and Adolescent Psychiatry, a well-documented appeal that includes rating scale data, treatment history, and a clear rationale for the specific medication has a substantially higher approval rate than a generic "please approve this medication" letter 12.

Step 3: Request a state fair hearing. If the plan-level appeal fails, every Medicaid beneficiary has the right to a state fair hearing. This is an independent review by a state administrative law judge or hearing officer. The plan's medical director must justify the denial against the state's coverage criteria. The fair hearing process is free. Data from multiple states show that Medicaid fair hearings overturn MCO denials in approximately 30-40% of cases where the beneficiary actually appears 13.

Step 4: Contact your state's Medicaid ombudsman. Every state has an ombudsman or beneficiary assistance program that can help you understand and exercise your appeal rights at no cost.

Alternatives to Vyvanse That Amerigroup May Prefer

If Amerigroup requires step therapy or denies Vyvanse, understanding the alternatives helps you and your prescriber make an informed decision about next steps. The stimulant medication class is large, and several options have strong evidence.

Methylphenidate extended-release (generic Concerta, Metadate CD, others). Methylphenidate is the most commonly prescribed first-line stimulant worldwide. A Cochrane systematic review (Storebø et al., 2015, 185 trials, N=12,245 children and adolescents) found that methylphenidate reduced ADHD symptoms with moderate-to-large effect sizes, though the overall quality of evidence was rated low due to risk of bias 14. For many patients, methylphenidate ER provides adequate symptom control and is universally available as a preferred generic on Amerigroup plans.

Mixed amphetamine salts extended-release (generic Adderall XR). This formulation contains a mixture of amphetamine salts and provides duration of action similar to Vyvanse (10-12 hours). It is available as an inexpensive generic and is preferred on most Amerigroup formularies. The pharmacokinetic profile differs from lisdexamfetamine because it does not require prodrug activation, which means onset of action is somewhat faster and the abuse liability profile is different.

Dexmethylphenidate extended-release (generic Focalin XR). This is the d-isomer of methylphenidate, available as a generic. It may be effective at half the dose of racemic methylphenidate.

Non-stimulant options. Atomoxetine (generic Strattera), guanfacine ER (generic Intuniv), and clonidine ER (generic Kapvay) are non-stimulant alternatives that do not require the same level of prior authorization scrutiny. These medications generally have smaller effect sizes for ADHD symptoms than stimulants. A meta-analysis by Cortese et al. (2018) in The Lancet Psychiatry (N=10,068 children across 133 trials) confirmed that amphetamines were the most efficacious pharmacological treatment for ADHD in children, while methylphenidate had the best balance of efficacy and tolerability 15.

The clinical decision about which medication to try first should be based on the patient's symptom profile, prior treatment history, comorbidities, and preference. Step therapy requirements do not change the medical evidence; they change the administrative sequence.

Tips for Maximizing Your Chances of Amerigroup Approval

Several practical steps increase the likelihood of a smooth approval process. Start by asking your prescriber to check the Amerigroup formulary before writing the prescription. If generic lisdexamfetamine is preferred in your state, write for the generic. If step therapy is required and the patient has not tried a first-step agent, consider starting with the required medication unless there is a documented clinical reason to skip it (contraindication, prior adverse reaction, or prior adequate trial).

Document everything. The single most common reason for PA denials is incomplete documentation. Your prescriber should include the diagnosis, date of diagnosis, current symptom severity (ideally with a standardized rating scale score), current functional impairment, all prior medication trials with dates and outcomes, and a clear statement of medical necessity.

Keep records of all communications with Amerigroup, including reference numbers for phone calls, copies of PA submissions, and denial letters. If you are a parent managing your child's medication, keep a medication diary that tracks symptoms, side effects, and functional outcomes. This documentation strengthens any appeal.

"Stimulant medications remain a cornerstone of evidence-based ADHD treatment, and access barriers should be addressed through systematic documentation and appropriate use of the appeals process rather than abandonment of effective therapy," according to the AAP's 2019 clinical practice guideline update 6.

Dr. Timothy Wilens, chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "The prodrug mechanism of lisdexamfetamine provides a clinical advantage in patients who need smoother pharmacokinetic coverage throughout the day or who have a history of stimulant misuse concerns" 4.